Cytokinetics (CYTK) Balance Sheet

Click line-items for a historical chart and %

Current assets:
Cash and cash equivalents
Short-term investments
Related party accounts receivable
Prepaid and other current assets
Total current assets
Long-term investments
Property and equipment, net
Restricted cash
Other assets
Total assets
Current liabilities:
Accounts payable
Accrued liabilities
Related party payables and accrued liabilities
Short-term portion of equipment financing lines
Deferred revenue
Total current liabilities
Long-term portion of equipment financing lines
Total liabilities
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value: Authorized:10,000,000 shares at June 30, 2011 and December 31, 2010 Issued and outstanding: Series A Convertible Preferred Stock - 8,070 shares at June 30, 2011 and zero shares at December 31,2010
Common stock, $0.001 par value: Authorized: 170,000,000 shares at June 30, 2011 and December 31, 2010 Issued and outstanding: 72,279,751 shares at June 30, 2011 and 66,907,600 shares at December 31, 2010
Additional paid-in capital
Accumulated other comprehensive income (loss)
Deficit accumulated during the development stage
Total stockholders' equity
Total liabilities and stockholders' equity

Entities mentioned with CYTK